Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Pre-Tax Margin
Income before tax as a percentage of revenue.
Sagimet Biosciences Inc.NASDAQ: SGMT
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin not reported for Q1 FY2026
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2023
- -1393.8%
- Year-over-year change
- —
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | — | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | -1393.8% | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Pre-Tax Margin vs competitors
How SGMT compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -9.0% | +113.7 pp | — | |
| LTM Mar 2026 | -173.5% | -122.7 pp | -103.0 pp | |
| LTM Mar 2026 | -266.9% | +75.4 pp | +325.9 pp | |
| LTM Mar 2026 | -319.3% | -193.8 pp | -182.8 pp | |
| LTM Mar 2026 | -2878.3% | -2892.1 pp | — | |
| LTM Mar 2026 | -4840.8% | -3838.0 pp | -1239.0 pp | |
SGMTSagimet Biosciences Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ZURAZura Bio Limited | FY2025 | — | — | — |
| Peer median (excluding SGMT) | -293.1% | -158.3 pp | -142.9 pp | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 2M | 0 | 0 |
| Gross Margin | — | — | 100.0% | — | — |
| Research & Development | 19.34M | 24.92M | 19.78M | 38.44M | 39.05M |
| Selling, General & Admin | 4.38M | 6.14M | 12.96M | 16.01M | 17.84M |
| Operating Expenses | 23.72M | 31.06M | 32.74M | 54.45M | 56.89M |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| EBITDA | (24.44M) | (30.37M) | (27.88M) | (45.57M) | (51.04M) |
| EBITDA Margin | — | — | -1393.8% | — | — |
| Operating Income | (23.72M) | (31.06M) | (30.74M) | (54.45M) | (56.89M) |
| Operating Margin | — | — | -1537.0% | — | — |
| Interest Income | 26K | 553K | 2.86M | 8.89M | 5.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (723K) | 556K | 2.86M | 8.89M | 5.85M |
| Income Before Tax | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Pre-Tax Margin | — | — | -1393.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Net Margin | — | — | -1393.8% | — | — |
| EPS (Basic) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| EPS (Diluted) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| Weighted Avg Shares | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
| Weighted Avg Shares (Diluted) | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.